Joseph Truitt was appointed Director of Century Therapeutics, Inc., effective September 9, 2026. As of November 6, 2026, Century Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 9, 2026, naming 1 appointment (Form 8-K, September 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Century Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Century Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Century Therapeutics, Inc. files it.
Also on the record for Century Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 7.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 3.3% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 6.8% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13G, by Commodore Capital LP | 7.1% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13G, by Venrock Healthcare Capital Partners III, L.P. | 7.1% of the class | 5%+ stakes | Source |
| January 15, 2026 | Stake report, Schedule 13G, by Chen Yu | 9.9% of the class | 5%+ stakes | Source |
| January 15, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 7.34% of the class | 5%+ stakes | Source |
| January 5, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Bain Capital Life Sciences Opportunities III, LP | 4.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Century Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Century Therapeutics, Inc. and the records around it.
Century Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Who owns it
Companies that share a holder
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: CABALETTA BIO, INC. (Aug 2026), KYVERNA THERAPEUTICS, INC. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Century Therapeutics, Inc.
Get an email when Century Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Century Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Century Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Century Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-09 | In | Director | 2026-09-09 | 8-K, 2026-09-09 |
Who leads Century Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Joseph Truitt, appointed, effective 2026-09-09 (filed 2026-09-09).
New leaders reset buying decisions — get the Full Report on Century Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Century Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Century Therapeutics, Inc.Every change, in the filing's words
Appointed: Joseph Truitt, Director, effective 2026-09-09
On September 9, 2026, the Board of Directors (the "Board") of Century Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to seven directors and appointed Mr. Joseph Truitt as a member of the Board, effective as of September 9, 2026 (the "Effective Date").
- Mr. Truitt will serve as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders, or until his successor is duly elected and qualified or until his earlier resignation, death or removal.
- Mr. Truitt will serve as a member of the Compensation Committee of the Board.
- Mr. Truitt, 62, currently serves as Chief Executive Officer of iECURE, Inc., a gene editing company, a role he has held since March 2021.
- Since May 2020, Mr. Truitt has served as a member of the board of directors of Larimar Therapeutics, Inc. (Nasdaq: LRMR).
- Mr. Truitt has also served as a director of Code Biotherapeutics, Inc., a gene therapy development company, since December 2020.
- From May 2018 until April 2020, Mr. Truitt served as President, Chief Executive Officer and member of the board of directors of Achillion Pharmaceuticals, Inc. ("Achillion", formerly Nasdaq: ACHN), a clinical-stage biopharmaceutical company developing small molecule drug therapies for immune system disorders, which was acquired by Alexion Pharmaceuticals, Inc., a global biopharmaceutical company, in January 2020.
- From April 2020 through December 2020, Mr. Truitt served as Chief Executive Officer of BioSpecifics Technologies Corp. (formerly Nasdaq: BSTC), a biopharmaceutical company that develops collagenase-based therapies, which was acquired by Endo International plc in December 2020.
Tools for this story
Each opens in a new tab, filled in for Century Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.